Home/ActiTrexx/Franz-Joseph Schneider, PhD

FS

Franz-Joseph Schneider, PhD

Chief Knowledge Officer, Co-Founder

Therapeutic Areas

Autoimmune Diseases Autoinflammatory Diseases Transplant Rejection

ActiTrexx Pipeline

Drug	Indication	Phase
ATreg/Actileucel (ATX-002)	Prevention of Graft-versus-Host Disease (GvHD)	Phase 1/2

Leadership Team at ActiTrexx

Prof. Andrea Tüttenberg, MD

Chief Executive Officer / Managing Director, Chief Medical Officer, Co-Founder

Helmut Jonuleit, PhD

Chief Scientific Officer, Co-Founder

View full ActiTrexx profile